Dizal Jiangsu Pharmaceutical Co Ltd
SSE:688192
| US |
|
Fubotv Inc
NYSE:FUBO
|
Media
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
| US |
|
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
| CN |
|
NIO Inc
NYSE:NIO
|
Automobiles
|
| US |
|
Fluor Corp
NYSE:FLR
|
Construction
|
| US |
|
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
| US |
|
TopBuild Corp
NYSE:BLD
|
Consumer products
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
Health Care
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
| US |
|
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
| US |
|
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
| US |
|
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
| US |
|
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
| US |
|
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
27.15
52.5
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CNY.
Choose the stock you wish to monitor with a price alert.
|
|
Fubotv Inc
NYSE:FUBO
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
C
|
C3.ai Inc
NYSE:AI
|
US |
|
|
Uber Technologies Inc
NYSE:UBER
|
US |
|
|
NIO Inc
NYSE:NIO
|
CN |
|
|
Fluor Corp
NYSE:FLR
|
US |
|
|
Jacobs Engineering Group Inc
NYSE:J
|
US |
|
|
TopBuild Corp
NYSE:BLD
|
US |
|
|
Abbott Laboratories
NYSE:ABT
|
US |
|
|
Chevron Corp
NYSE:CVX
|
US |
|
|
Occidental Petroleum Corp
NYSE:OXY
|
US |
|
|
Matrix Service Co
NASDAQ:MTRX
|
US |
|
|
Automatic Data Processing Inc
NASDAQ:ADP
|
US |
|
|
Qualcomm Inc
NASDAQ:QCOM
|
US |
|
|
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Dizal Jiangsu Pharmaceutical Co Ltd
Other Current Liabilities
Dizal Jiangsu Pharmaceutical Co Ltd
Other Current Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
D
|
Dizal Jiangsu Pharmaceutical Co Ltd
SSE:688192
|
Other Current Liabilities
¥57.2m
|
CAGR 3-Years
76%
|
CAGR 5-Years
17%
|
CAGR 10-Years
N/A
|
|
|
Beigene Ltd
HKEX:6160
|
Other Current Liabilities
¥1.5B
|
CAGR 3-Years
-7%
|
CAGR 5-Years
26%
|
CAGR 10-Years
N/A
|
|
|
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
|
Other Current Liabilities
¥1.9B
|
CAGR 3-Years
53%
|
CAGR 5-Years
54%
|
CAGR 10-Years
N/A
|
|
|
Shanghai RAAS Blood Products Co Ltd
SZSE:002252
|
Other Current Liabilities
¥343.5m
|
CAGR 3-Years
27%
|
CAGR 5-Years
12%
|
CAGR 10-Years
27%
|
|
|
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
|
Other Current Liabilities
¥2.5B
|
CAGR 3-Years
19%
|
CAGR 5-Years
74%
|
CAGR 10-Years
62%
|
|
|
Imeik Technology Development Co Ltd
SZSE:300896
|
Other Current Liabilities
¥121.8m
|
CAGR 3-Years
33%
|
CAGR 5-Years
72%
|
CAGR 10-Years
N/A
|
|
Dizal Jiangsu Pharmaceutical Co Ltd
Glance View
Dizal (Jiangsu) Pharmaceutical Co., Ltd. engages in the discovery, development, and commercialization of innovative medicines. The company is headquartered in Shanghai, Shanghai and currently employs 328 full-time employees. The company went IPO on 2021-12-10. The firm focuses on diseases such as malignant tumors and immune diseases. The main candidate innovative drugs in the Company's research and development (R&D) pipeline are DZD4205, DZD9008, DZD1516, DZD2269, DZD8586, DZD0095. The firm is still in the R&D stage.
See Also
What is Dizal Jiangsu Pharmaceutical Co Ltd's Other Current Liabilities?
Other Current Liabilities
57.2m
CNY
Based on the financial report for Dec 31, 2023, Dizal Jiangsu Pharmaceutical Co Ltd's Other Current Liabilities amounts to 57.2m CNY.
What is Dizal Jiangsu Pharmaceutical Co Ltd's Other Current Liabilities growth rate?
Other Current Liabilities CAGR 5Y
17%
Over the last year, the Other Current Liabilities growth was 154%. The average annual Other Current Liabilities growth rates for Dizal Jiangsu Pharmaceutical Co Ltd have been 76% over the past three years , 17% over the past five years .
You don't have any saved screeners yet
